These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 27484756

  • 1. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S, Patel S, Crowe S, von Eynatten M.
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):886-92. PubMed ID: 27484756
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M.
    Clin Ther; 2014 Nov 01; 36(11):1595-605. PubMed ID: 25236917
    [Abstract] [Full Text] [Related]

  • 3. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes.
    Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N.
    Cardiovasc Diabetol; 2017 Jan 21; 16(1):13. PubMed ID: 28109295
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
    Wang W, Yang J, Yang G, Gong Y, Patel S, Zhang C, Izumoto T, Ning G.
    J Diabetes; 2016 Mar 21; 8(2):229-37. PubMed ID: 25753488
    [Abstract] [Full Text] [Related]

  • 5. Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2™ Trial). Rationale, Design, and Baseline Characteristics of the Study Population.
    Giorda CB, Cioffi G, Lucci D, Nada E, Ognibeni F, Mancusi C, Latini R, Maggioni AP, DYDA 2 Investigators.
    Cardiovasc Drugs Ther; 2019 Oct 21; 33(5):547-555. PubMed ID: 31418140
    [Abstract] [Full Text] [Related]

  • 6. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 7. DPP-4 inhibitor treatment: β-cell response but not HbA1c reduction is dependent on the duration of diabetes.
    Kozlovski P, Bhosekar V, Foley JE.
    Vasc Health Risk Manag; 2017 Mar 14; 13():123-126. PubMed ID: 28408838
    [Abstract] [Full Text] [Related]

  • 8. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M.
    Postgrad Med; 2016 Nov 14; 128(8):747-754. PubMed ID: 27684308
    [Abstract] [Full Text] [Related]

  • 9. Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).
    Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ.
    Diab Vasc Dis Res; 2015 May 14; 12(3):164-74. PubMed ID: 25780262
    [Abstract] [Full Text] [Related]

  • 10. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH, Feng ZK, Xu LH.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):588-594. PubMed ID: 28789492
    [Abstract] [Full Text] [Related]

  • 11. Effect of Linagliptin on Glycemic Control in Chinese Patients with Newly-Diagnosed, Drug-Naïve Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
    Wu W, Li Y, Chen X, Lin D, Xiang S, Shen F, Gu X.
    Med Sci Monit; 2015 Sep 09; 21():2678-84. PubMed ID: 26350766
    [Abstract] [Full Text] [Related]

  • 12. Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial.
    Tripolt NJ, Aberer F, Riedl R, Url J, Dimsity G, Meinitzer A, Stojakovic T, Aziz F, Hödl R, Brachtl G, Strunk D, Brodmann M, Hafner F, Sourij H.
    Cardiovasc Diabetol; 2018 May 17; 17(1):71. PubMed ID: 29773079
    [Abstract] [Full Text] [Related]

  • 13. Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes.
    Sarashina A, Friedrich C, Crowe S, Patel S, Graefe-Mody U, Hayashi N, Horie Y.
    J Diabetes Investig; 2016 Sep 17; 7(5):744-50. PubMed ID: 27180969
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials.
    Thrasher J, Kountz DS, Crowe S, Woerle HJ, von Eynatten M.
    Postgrad Med; 2015 Jun 17; 127(5):419-28. PubMed ID: 25840727
    [Abstract] [Full Text] [Related]

  • 15. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb 17; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
    Mu Y, Pan C, Fan B, Hehnke U, Zhang X, Zhang X, Wang X, Liu J, Zhang Y, Du J, Ma J, Gong Y.
    Diabetes Res Clin Pract; 2017 Feb 17; 124():48-56. PubMed ID: 28088030
    [Abstract] [Full Text] [Related]

  • 17. A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score.
    Bonora E, Bryzinski B, Hirshberg B, Cook W.
    Nutr Metab Cardiovasc Dis; 2016 May 17; 26(5):374-9. PubMed ID: 27033025
    [Abstract] [Full Text] [Related]

  • 18. Does the treatment of type 2 diabetes mellitus with the DPP-4 inhibitor vildagliptin reduce HbA1c to a greater extent in Japanese patients than in Caucasian patients?
    Foley JE, Bhosekar V, Kawamori R.
    Vasc Health Risk Manag; 2016 May 17; 12():9-12. PubMed ID: 26855580
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and tolerability of linagliptin added to a sulfonylurea regimen in patients with inadequately controlled type 2 diabetes mellitus: an 18-week, multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ, Arvay L, Liu D, Patel S, von Eynatten M, Woerle HJ.
    Clin Ther; 2012 Sep 17; 34(9):1909-19.e15. PubMed ID: 22939034
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE.
    Can J Diabetes; 2016 Feb 17; 40(1):50-7. PubMed ID: 26474870
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.